Avalo Therapeutics (AVTX) Competitors

Avalo Therapeutics (NASDAQ:AVTX) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, community ranking, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Do insiders and institutionals hold more shares of AVTX or AQST?

87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are owned by institutional investors. 0.3% of Avalo Therapeutics shares are owned by insiders. Comparatively, 7.9% of Aquestive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Does the media favor AVTX or AQST?

In the previous week, Avalo Therapeutics had 2 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 5 mentions for Avalo Therapeutics and 3 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 1.30 beat Avalo Therapeutics' score of 0.40 indicating that Aquestive Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aquestive Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer AVTX or AQST?

Avalo Therapeutics currently has a consensus target price of $29.00, suggesting a potential upside of 243.60%. Aquestive Therapeutics has a consensus target price of $11.00, suggesting a potential upside of 265.45%. Given Aquestive Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aquestive Therapeutics is more favorable than Avalo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Aquestive Therapeutics	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14

Is AVTX or AQST more profitable?

Avalo Therapeutics has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -59.75%. Aquestive Therapeutics' return on equity of 0.00% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-442.16%	122.99%
Aquestive Therapeutics	-59.75%	N/A	-33.96%

Which has more volatility & risk, AVTX or AQST?

Avalo Therapeutics has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500. Comparatively, Aquestive Therapeutics has a beta of 2.67, meaning that its share price is 167% more volatile than the S&P 500.

Which has preferable earnings and valuation, AVTX or AQST?

Aquestive Therapeutics has higher revenue and earnings than Avalo Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$820K	106.98	-$31.54M	N/A	N/A
Aquestive Therapeutics	$50.58M	5.43	-$7.87M	-$0.45	-6.69

Does the MarketBeat Community believe in AVTX or AQST?

Aquestive Therapeutics received 204 more outperform votes than Avalo Therapeutics when rated by MarketBeat users. Likewise, 68.17% of users gave Aquestive Therapeutics an outperform vote while only 40.00% of users gave Avalo Therapeutics an outperform vote.

Company	Underperform	Outperform
Avalo Therapeutics	Outperform Votes 8 40.00%	Underperform Votes 12 60.00%
Aquestive Therapeutics	Outperform Votes 212 68.17%	Underperform Votes 99 31.83%

Summary

Aquestive Therapeutics beats Avalo Therapeutics on 12 of the 17 factors compared between the two stocks.